Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Background Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR mu...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Pathologists & the Korean Society for Cytopathology
2022-09-01
|
Series: | Journal of Pathology and Translational Medicine |
Subjects: | |
Online Access: | http://www.jpatholtm.org/upload/pdf/jptm-2022-06-11.pdf |